LYPHOMED AND VESTAR LIPOSOME COLLABORATION TO CONTINUE
Executive Summary
LYPHOMED AND VESTAR LIPOSOME COLLABORATION TO CONTINUE under a new agreement in-principle, announced Nov. 14. "All costs and profits of the joint venture will continue to be shared equally by LyphoMed and Vestar, but primary responsibilities for clinical research and marketing have been more specifically allocated between the parties," the companies stated in a joint release. Vestar, in late September, submitted a notice of termination of its original R&D agreement with LyphoMed ("The Pink Sheet" Oct. 3, T&G-5). That agreement was announced in March 1987. In September, Vestar characterized its communications with LyphoMed as "poor" and maintained that the generic injectables manufacturer had been "unwilling to hold discussions concerning the differences between the parties." The new agreement gives Vestar responsibility for clinical research on liposomal Amphotericin-B in North America and Europe. LyphoMed will be responsible for the clinical development of Amphotericin-B in Japan and for liposomal doxorubicin worldwide. Marketing responsibility for liposomal Amphotericin-B in Europe goes to Vestar and in the rest of the world to LyphoMed, which will also market the doxorubicin product worldwide. "Certain operational changes will also be made in the joint venture," the release notes.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth